Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

Huntington's disease (HD) is characterized by gradually evolving selective neuronal death. Several lines of evidence suggest that an excitotoxic mechanism may play a role. Tryptophan metabolism leads to production of quinolinic acid, an N-methyl-D-aspartate (NMDA) receptor agonist, and to kynurenic acid, an antagonist at these same receptors. We recently found increased kynurenine to kynurenic acid ratios in HD postmortem putamen and decreased kynurenic acid concentrations in cerebrospinal fluid, consistent with decreased formation of kynurenic acid in HD brain. In the present study we used HPLC with 16 sensor coulometric electrochemical detection to measure kynurenic acid and 18 other electrochemically active compounds in 6 cortical regions, caudate and cerebellum from controls, HD, Alzheimer's disease (AD), and Parkinson's disease (PD) patients. Significant reductions in kynurenic acid concentrations were found in 5 of 6 cortical regions examined. Smaller reductions of kynurenic acid in the caudate, cerebellum and frontal pole were not significant. No significant reductions were found in the AD and PD patients. Both uric acid and glutathionine were significantly reduced in several regions of HD cerebral cortex, which could signify abnormal energy metabolism in HD. Since kynurenic acid is an antagonist of excitatory amino acid receptors, a deficiency could contribute to the pathogenesis of neuronal degeneration in HD.

[1]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[2]  M. Beal,et al.  Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. , 1987, Brain : a journal of neurology.

[3]  A. Novelli,et al.  Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.

[4]  Y. Agid,et al.  Mitochondrial function and parental sex effect in Huntington's disease , 1990, The Lancet.

[5]  E. Bird,et al.  Regional Mitochondrial Respiratory Activity in Huntington's Disease Brain , 1985, Journal of neurochemistry.

[6]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[7]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[8]  G. Reynolds,et al.  Brain Quinolinic Acid in Huntington's Disease , 1988, Journal of neurochemistry.

[9]  F. Moroni,et al.  Increase in Kynurenic Acid in Huntington's Disease Motor Cortex , 1989, Journal of neurochemistry.

[10]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[11]  T. Noguchi,et al.  Kynurenine pyruvate transaminase in rat brain , 1974, Journal of neurochemistry.

[12]  K. R. Maples,et al.  Free radical metabolite of uric acid. , 1988, The Journal of biological chemistry.

[13]  M. Beal,et al.  Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  C D Marsden,et al.  Dopa‐responsive dystonia , 1991, Neurology.

[15]  R. Myers,et al.  Morphometric analysis of prefrontal cortex in Huntingtonʼs disease (HD): 256 , 1990 .

[16]  P. Wood,et al.  In Vivo Modulation of the N‐Methyl‐D‐Aspartate Receptor Complex by D‐Serine: Potentiation of Ongoing Neuronal Activity as Evidenced by Increased Cerebellar Cyclic GMP , 1989, Journal of neurochemistry.

[17]  G. Lombardi,et al.  Presence of Kynurenic Acid in the Mammalian Brain , 1988, Journal of neurochemistry.

[18]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[19]  E. Costa,et al.  Modulation of glutamate receptors by phencyclidine and glycine in the rat cerebellum: cGMP increase in vivo , 1989, Brain Research.

[20]  M. Beal,et al.  Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. , 1990, Analytical biochemistry.

[21]  E. Flamm,et al.  Free radicals in cerebral ischemia. , 1978, Stroke.

[22]  M. Yoshiura,et al.  Xanthine and Uric Acid Levels in Rat Brain Following Focal Ischemia , 1988, Journal of neurochemistry.

[23]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[24]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[25]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[26]  S. Udenfriend,et al.  Fluorometric assay of proteins in the nanogram range. , 1973, Archives of biochemistry and biophysics.

[27]  R. Schwarcz,et al.  Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia , 1988, Annals of neurology.

[28]  C. Grossman,et al.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.

[29]  L. Iversen,et al.  Huntington's Chorea , 1974 .

[30]  M. Beal,et al.  Neurochemical characterization of excitotoxin lesions in the cerebral cortex , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  B. Hyman,et al.  Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism , 1991, Journal of neurochemistry.

[32]  M. Hayden,et al.  The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease , 1987, Neurology.

[33]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[34]  P. Ascher,et al.  Glycine potentiates the NMDA response in cultured mouse brain neurons , 1987, Nature.

[35]  T. Salt Modulation of NMDA receptor-mediated responses by glycine and d-serine in the rat thalamus in vivo , 1989, Brain Research.

[36]  G. Zeevalk,et al.  Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. , 1990, The Journal of pharmacology and experimental therapeutics.

[37]  Z. Kamiński,et al.  Effect of NADH on hypoxanthine hydroxylation by native NAD+-dependent xanthine oxidoreductase of rat liver, and the possible biological role of this effect. , 1981, The Biochemical journal.

[38]  R. Schwarcz,et al.  Two kynurenine aminotransferases in human brain , 1991, Brain Research.

[39]  M. Beal,et al.  Kynurenine pathway abnormalities in Parkinson's disease , 1992, Neurology.

[40]  J. Parks,et al.  Evidence for a defect in NADH , 1990, Neurology.

[41]  A. Ellinger Die Entstehung der Kynurensäure. , 1905 .

[42]  J. Penney,et al.  NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.

[43]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[44]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[45]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[46]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[48]  R. Schwarcz,et al.  Identification and quantification of kynurenic acid in human brain tissue , 1988, Brain Research.

[49]  A. Thomson,et al.  Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices , 1989, Nature.

[50]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[51]  E. Costa,et al.  Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-d-aspartate-sensitive glutamate receptor domain , 1989, Neuroscience Letters.

[52]  R. Dingledine,et al.  Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. , 1988, Science.

[53]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[54]  M. Beal,et al.  EC array sensor concepts and data. , 1987, Life sciences.

[55]  R. Schwarcz,et al.  Rat Brain Slices Produce and Liberate Kynurenic Acid upon Exposure to l‐Kynurenine , 1989, Journal of neurochemistry.

[56]  R. Schwarcz,et al.  3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  L. Iversen,et al.  7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Stone,et al.  Quinolinic acid and other kynurenines in the central nervous system , 1985, Neuroscience.

[59]  M. Beal,et al.  Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease , 1991, Neuroscience Letters.

[60]  M. Cudkowicz,et al.  Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.

[61]  Joseph B. Martin,et al.  Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions , 1989, Synapse.

[62]  A. Homer THE CONSTITUTION OF KYNURENIC ACID , 1914 .